Former Site Leader and Vice President for Global Marketing at Medtronic/Covidien Vascular Therapies

As a medical device leader and strategic marketing executive, Robert Rajalingam has been selected to lead Smith Medical’s $300 M Vascular Access business.

Life Science Partner collaborated closely with Vice President, Carl Stamp to recruit Rajalingam from Medtronic.

Vascular medicine has been his passion and interest, having worked both in the venous therapy area (spearheading the re-branding with Rethink Varicose Veins campaign including an Olympic spokesperson at Covidien) and in arterial disease at Medtronic Vascular in business development, including a partnership with Abbott Vascular.

“Robert is passionate and articulate about medical devices and their ability to improve patient lives. Experienced in managing a maturing product portfolio while simultaneously spearheading product innovation, he has the know-how, tenacity, and marketing instincts to build highly effective teams at Smiths Medical,” states Tom Callaway, MD, Founder and President of Life Science Partner.

Rajalingam earned his Bachelor of Science in Engineering degree from Duke University and his MBA from Stanford Graduate School of Business.

Former Senior Vice President, Chief Regulatory Officer at Medtronic

As one of the foremost leaders in the complex regulatory arena of medical devices, combination products, and healthcare information, Susan Alpert, MD, PhD, has been recruited by Life Science Partner to serve as the top regulatory advisor for Canary Medical.

Canary Medical has established an innovative portfolio of intellectual property surrounding its CHIRP (Canary Medical Implantable Recording Processor) technology that is transforming the medical field as it allows medical device manufacturers to integrate a 1cc implanted device for wireless data transmission.

“As a seasoned expert within the inner workings of the FDA on healthcare data and appropriate management of patient information, the regulatory role at Canary will be a natural fit for Alpert following her retirement from Medtronic,” states Tom Callaway, MD, President of Life Science Partner.  “Alpert will be an invaluable source for Canary’s rapidly growing company and current leadership team- Bill Hunter, CEO and Jeff Gross, CTO.

Susan completed her bachelor’s degree at Barnard College, Columbia University in New York City and holds a master’s degree and Ph.D. in Biomedical Sciences from New York University.

She received her medical degree from the University of Miami (Florida) and completed her clinical training at Montefiore Medical Center in the Bronx, New York and at Children’s National Medical Center in Washington, D.C.

Former Medical Director, Global Medical Marketing, ConvaTec

Life Science Partner recruited Michel Hermans, MD, a surgically trained medical affairs executive to become Chief Medical Officer for TissueTech.

Hermans joins TissueTech after serving as a biopharma consultant for his own firm and Medical Director, Global Medical Marketing for ConvaTech.   Previously, Hermans served served as Medical Director for Ortec where he successfully led the new clinical trials for the commercialization of OrCel globally.

TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, orthopedic reconstructive surgeries and wound care markets.

TissueTech offers its portfolio products through its commercial entities: BioTissue, Inc., the industry leader in regenerative tissue therapies for ocular surface diseases and disorders, and Amniox Medical, a leading technology provider to the orthopedic and wound care markets.

“Hermans has the direct clinical trials management experience that leads to the approval of biologics in the BLA regulatory pathway – and brings that background to TissueTech’s clinical and regulatory strategy,” states Tom Callaway, MD, Founder and President of Life Science Partner.  “In addition, as a specialist in treating burn patients, he brings real-life clinical experience to the company.”

Hermans earned his Medical Degree from the University of Groningen in the Netherlands and completed his training in general surgery, burn and trauma care from the Rode Kruis Ziekenhuis and Burn Center in Beverwijk, Netherlands.

Former President and Chief Executive Officer of Vascular Pathways

Life Science Partner has recruited Bill Bold, former CEO of Vascular Pathways and senior medical device leader, to become Chief Executive Officer for Vestagen, an innovator in the development of Active Barrier fabrics and protection technology to protect the healthcare worker.

Prior to joining Vestagen, Bold turned around Vascular Pathways with product innovation and commercialization and sold the company to CR Bard for its best-in-class portfolio of peripheral vascular access technologies. “Bold is an articulate, strategic and a strong leader who recruits world-class teams to early-stage companies,” stated Tom Callaway, MD, Founder and President of Life Science Partner and Venture Partner at HealthQuest Capital, an investor in the company.

“With a track record for delivering a strong return on investment in fundraising with venture capital and private equity, Bold has the experience to lead Vestagen’s growth and profitability within the healthcare industry,” noted Callaway.

Prior to joining Vascular Pathways, Bold held executive leadership roles for both early stage and corporate divisions of medical device companies such as Access Scientific, Venetec, Medibuy and CR Bard.

Bold earned a Bachelor of Science Degree in Marketing from West Chester University.

Learn More About Life Science Partner

Click button below to find out more about how we recruit Chief Executives:

Former Senior Director, Global Safety Officer at The Medicines Company

Life Science Partner recruited Yanshan Ma, MD, PhD, to become Senior Director, Medical Safety Physician, Internal Medicine and Infectious Diseases for Allergan. 

In her new role Dr. Ma will be responsible for the group’s safety strategy, pharmacovigilance and medical risk management.

Dr. Ma joins Allergan after leading a cross-functional safety management team at The Medicines Company where she was responsible for ensuring accurate safety evaluation and signal detection.  She’s been a key member in the growth of The Medicines Company.

“Dr. Ma has hands-on leadership experience of both small groups and matrix organizations of physicians and safety scientists,” commented Tom Callaway, MD, Founder and President of Life Science Partner.  “She has the work ethic and pharmacovigilence knowledge that will fit nicely with the entrepreneurial environment of Allergan.”

Dr. Ma earned her PhD in Biochemistry from East Tennessee State University’s James E. Quillen College of Medicine and her MD from Sun Yat-sen University of Medical Sciences in China.

DANVERS, Mass., Oct. 08, 2015 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Seth Bilazarian, M.D. will be appointed as Vice President of Interventional Cardiology Programs, effective October 8, 2015.

“We are excited to welcome Dr. Seth Bilazarian to Abiomed, where he will add a specialized interventional cardiology perspective to the executive team that will further strengthen our mission to recover hearts and save lives. Seth has over 20 years of experience practicing interventional cardiology in the cath lab and has developed an expertise in hemodynamic support. His insight and knowledge will richly enhance our ongoing training and education initiatives for the new standard of care,” said Michael R. Minogue, President, Chairman and Chief Executive Officer, Abiomed.

“I am thrilled to become part of the Abiomed team. As a user, I am very familiar with the benefits of Impella and know it is transforming the standard of care in treating complex patients. I am eager to collaborate with expert and experienced physician users in interventional cardiology and heart failure to develop best practices for use of the Impella platform in Protected PCI,” said Seth Bilazarian, M.D.  “Educating physicians more broadly on the safe, effective and appropriate use of this technology will also be a focus. I am equally enthusiastic about the opportunity to begin working with industry colleagues to bring new devices within the Impella platform to market and continue the collaborative mission of recovering hearts.”

Dr. Bilazarian is a clinical and interventional cardiologist and has performed coronary and peripheral interventions at Lahey Clinic, Boston University Medical Center and Massachusetts General Hospital and was Director of the Cardiac Catheterization Laboratory (Cath Lab) and Chief of the Cardiovascular Steering Committee at Lawrence General. Most recently, he was the Director of Clinical Cardiology Research Program and Clinical Cardiologist at Pentucket Medical Associates, LLC. He also serves on the faculty as an instructor in medicine at Harvard Medical School, where he has taught since 1995 and is the founder and director of the largest community based cardiac research program in the Partner’s network.

Dr. Bilazarian is board certified in cardiovascular medicine, nuclear cardiology, vascular ultrasound, interventional cardiology, and vascular and endovascular medicine. Dr. Bilazarian is an active participant in outpatient clinical trials in congestive heart failure, hypertension, heart disease prevention, diabetes, anemia, atrial fibrillation, anti-inflammatory strategies for vascular prevention and anticoagulation and anti-platelet therapies. In 2008, he was appointed as physician advisor to the cardiac device panel of the Food & Drug Administration.

In addition to his clinical practice, Dr. Bilazarian is an active blogger in the physician community. His blog, “Practitioner’s Corner with Dr. Seth Bilazarian” was established in 2009 and is hosted on theheart.org and MedScape (http://goo.gl/k5lZqA). He has written over 100 blog posts that cover various topics across the wide spectrum of interventional cardiology.

Dr. Bilazarian received a Bachelor of Science in Engineering in Chemical Engineering from Tufts University and MD from University of Massachusetts Medical School. He completed his internship and residency at The Johns Hopkins Hospital in Baltimore, and cardiology and interventional cardiology fellowship at Boston University Hospital and Boston City Hospital.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support.  Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.  For additional information please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements regarding our expectation of a smooth transition to a new Vice President and Chief Financial Officer, the Company’s expectations of continued commercial growth, and future opportunities, including the opportunity to become the standard of care.

The Company’s actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company’s filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K.

Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

For more information, please contact:

Aimee Genzler
Director, Corporate Communications
978-646-1553
agenzler@abiomed.com

Ingrid Goldberg
Director, Investor Relations
igoldberg@abiomed.com

Former Chief Medical Officer Rosetta Genomics

Life Science Partner recruited Bob Wassman, MD, to become Chief Medical Officer of Lineagen to lead The Company’s clinical direction, product strategy, medical affairs, and global trials and registration process for Lineagen’s products and services.

Previously, as Chief Medical Officer for Rosetta Genomics, Wassman played a critical role in building the commercial, clinical and reimbursement strategy for the Rosetta’s microRNA-based platform technologies. He partnered closely with CEO Ken Berlin to evaluate new technologies to build out a fully personalized medicine resulting in the acquisition of PersonalizedDx.

Wassman joined Rosetta after leading the pharmagenomics services program at CVS Caremark, after, It’s acquisition of Generation Health, to improve precision therapy management and guide program development. Throughout his career Wassman has served in several key genomic leadership roles for cutting edge companies such as Good Start Genetics, Celula, Genzyme, and Prometheus.

“With a successful track record in building CLIA-based laboratory businesses combining scientific and clinical knowledge, Wassman will be a critical asset for Lineagen’s future growth and development,” stated Tom Callaway, MD, President and Founder of Life Science Partner.

Wassman earned a Bachelor of Science Degree in Biology from Yale University and his MD from Albany Medical College.

Former Senior Director, Research and Development At Genzyme/Sanofi

Life Science Partner has recruited Gloria Matthews, DVM, PhD to become Chief Medical Officer at Histogenics.

In her new role Matthews will report directly to the Chief Executive Officer, Adam Gridley, and will serve as the senior physician within Histogenics responsible for clinical direction, product strategy, medical affairs, and strategic oversight of the global clinical trials for the Company’s products.

Mathews joins Histogenics from Genzyme/Sanofi where she led the global development team focused on two autologous cell therapies for cartridge repair including Carticel. She is a well published and leader in the field of regenerative medicine, with a corporate background that integrates fundamental science, clinical development, and global regulatory expertise.

“As a globally recognized thought leader for orthopedic R&D, Matthews has led global teams focused on regenerative medicine including US, Europe and Asia,” noted Tom Callaway, MD, President of Life Science Partner. “With her deep knowledge of cartilage regeneration and its challenges, Matthews will bring her considerable experience to help commercialize Histogenics’ portfolio.”

Matthews received her Bachelor of Science degree in biochemistry and Animal Science, as well as her PhD in Cell/Matrix Biology and DVM from Cornell University.

Former Director, Global Segmentation Program, GE Healthcare

Life Science Partner recruited Upayan SenGupta, MBA, an innovative senior medical device executive, to become Vice President and General Manager, Health Sciences for Underwriters Laboratories where he will lead The Company’s continued transformation of the Health Sciences business unit from a compliance and audit organization to a proactive participant in the registration and product development teams.

With over 15 years at GE Healthcare, SenGupta was most recently appointed to create and lead the newly formed Segmentation program focused on cutting-edge big data analytics to drive deeper customer centric process and product design.

During his tenure at GE, SenGupta strategically led partnerships across the Sales, Marketing and Supply Chain teams to simplify product offerings and cut costs to improve targeted solutions for customers worldwide. Throughout his career at GE, SenGupta provided innovative cross-functional leadership to The Company’s operations strategy, product development, supply chain planning and commercial operations.

“With a background in “internal consulting” to develop global manufacturing efficiencies and building new quality systems in one of the world’s largest healthcare products companies, SenGupta will be a major asset in his new role at Underwriters Laboratories,” stated Tom Callaway, MD, President and Founder of Life Science Partner.

SenGupta earned a Bachelor of Science Degree in Electrical and Computer Engineering with a minor in Economics from Purdue University and received his MBA from Northwestern University’s Kellogg School of Management.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives:

Improvement Advisor for Cynosure Health Joins Vestagen

Life Science Partner recruited Barb DeBaun, RN, MSN, CIC, to become Vice President, Clinical and Regulatory Affairs for Vestagen Technical Textiles, Inc.

DeBaun joins Vestagen after serving as an Improvement Advisor for Cynosure Health where she provided vision and leadership in the development, implementation and facilitation of performance improvement initiatives for healthcare organizations.

In her new role at Vestagen, DeBaun will serve as the senior clinical leader for The Company overseeing clinical direction, product strategy, medical affairs and key thought leader development. “DeBaun’s passion for protecting the healthcare worker from infection while providing quality care makes her a natural fit for Vestagen’s VP of Clinical and Regulatory Affairs,” states Tom Callaway, MD, Founder and President of Life Science Partner.

DeBaun earned her Bachelor of Science in Nursing from Pace University and her Master of Science in Nursing from San Francisco State University. DeBaun is an active member of APIC having served as the chair of the 2012 APIC Annual Conference Committee and as a member of the APIC Education Committee and the APIC Practice Guidance Council. In 2008, she was selected as Infection Control Today‘s Educator of the Year.